Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway

References

• Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma [comment editorial research support, Non-U.S. Gov't]. Haematologica. 2011;96(2):186–189.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875–885.
   PubMed Web of Science ®Google Scholar
• Gupta S, Yeh S, Chami R, et al. The prognostic impact of tumour-associated macrophages and Reed-Sternberg cells in paediatric Hodgkin lymphoma. Eur J Cancer. 2013;49(15):3255–3261.
   PubMed Web of Science ®Google Scholar
• Barros MH, Hassan R, Niedobitek G. Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein–Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res. 2012;18(14):3762–3771.
   PubMed Web of Science ®Google Scholar
• Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein–Barr virus status in classical Hodgkin's lymphoma [research support, Non-U. Gov't]. Haematologica. 2011;96(2):269–276.
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended Follow-Up of the multicohort Single-Arm phase II CheckMate 205 trial. J Clin Oncol. 2018; 36(14):1428–1439.
   PubMed Web of Science ®Google Scholar
• Henry M, Buck S, Savaşan S. Flow cytometry for assessment of the tumor microenvironment in pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2018;65(11):e27307.
   PubMed Web of Science ®Google Scholar
• Ozdemir O, Ravindranath Y, Savaşan S. Cell-mediated cytotoxicity evaluation using monoclonal antibody staining for target or effector cells with annexinV/propidium iodide colabeling by fluorosphere-adjusted counts on three-color flow cytometry. Cytometry A. 2003;56(1):53–60.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Targeting immune checkpoints in lymphoma. Curr Opin Hematol. 2015;22(4):337–342.
   PubMed Web of Science ®Google Scholar
• Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical hodgkin lymphoma. Blood. 2017;130(21):2265–2270.
   PubMed Web of Science ®Google Scholar
• Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29(14):1812–1826.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Alonso-Álvarez S, Vidriales MB, Caballero MD, et al. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. Leuk Lymphoma. 2017;58(5):1144–1152.
   PubMed Web of Science ®Google Scholar
• Oudejans JJ, Jiwa NM, Kummer JA, et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein–Barr virus-positive and -negative Hodgkin's disease. Blood. 1996;87(9):3844–3851.
   PubMed Web of Science ®Google Scholar
• Barros MH, Segges P, Vera-Lozada G, et al. Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival. PLoS One. 2015;10(5):e0124531.
   PubMed Web of Science ®Google Scholar
• Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood. 1997;89(4):1376–1382.
   PubMed Web of Science ®Google Scholar
• Chiu J, Ernst DM, Keating A. Acquired natural killer cell dysfunction in the tumor microenvironment of classic Hodgkin lymphoma. Front Immunol. 2018;9:267.
   PubMed Web of Science ®Google Scholar
• Reiners KS, Kessler J, Sauer M, et al. Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther. 2013;21(4):895–903.
   PubMed Web of Science ®Google Scholar
• Hsu J, Hodgins JJ, Marathe M, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128(10):4654–4668.
   PubMed Web of Science ®Google Scholar
• Vari F, Arpon D, Keane C, et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 2018;131(16):1809–1819.
   PubMed Web of Science ®Google Scholar
• Bellucci R, Martin A, Bommarito D, et al. Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015;4(6):e1008824.
   PubMed Web of Science ®Google Scholar
• Cader FZ, Hu X, Goh WL, et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med. 2020;26(9):1468–1479.
   PubMed Web of Science ®Google Scholar
• Rezvani K, editor CAR NK cells: a drive to the future of cell therapy. AACR Annual Meeting; 2021. Virtual.
   Google Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–3277.
   PubMed Web of Science ®Google Scholar
• Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111(6):3220–3224.
   PubMed Web of Science ®Google Scholar
• Sasse S, Reddemann K, Diepstra A, et al. Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment. Haematologica. 2019;104(1):e21–e24.
   PubMed Web of Science ®Google Scholar
• Cader FZ, Schackmann RCJ, Hu X, et al. Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment. Blood. 2018;132(8):825–836.
   PubMed Web of Science ®Google Scholar
• Wein F, Weniger MA, Hoing B, et al. Complex immune evasion strategies in classical Hodgkin lymphoma. Cancer Immunol Res. 2017;5(12):1122–1132.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018;36(10):942–950.
   PubMed Web of Science ®Google Scholar
• Oweida A, Hararah MK, Phan A, et al. Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration. Clin Cancer Res. 2018;24(21):5368–5380.
   PubMed Web of Science ®Google Scholar
• Nagasaki J, Togashi Y, Sugawara T, et al. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. Blood Adv. 2020;4(17):4069–4082.
   PubMed Web of Science ®Google Scholar
• Carey CD, Gusenleitner D, Lipschitz M, et al. Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130(22):2420–2430.
   PubMed Web of Science ®Google Scholar
• Aoki T, Chong LC, Takata K, et al. Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma. Cancer Discov. 2020;10(3):406–421.
   PubMed Web of Science ®Google Scholar
• Reinke S, Brockelmann PJ, Iaccarino I, et al. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood. 2020;136(25):2851–2863.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Carreras J, Higuchi H, et al. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia. 2020;34(9):2405–2417.
   PubMed Web of Science ®Google Scholar
• Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017; 545(7655):495–499.
   PubMed Web of Science ®Google Scholar
• Veldman J, Visser L, Huberts-Kregel M, et al. Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58. Blood. 2020;136(21):2437–2441.
   PubMed Web of Science ®Google Scholar